Am. J. Respir. Crit. Care Med., Volume 157, Number 6, June 1998, 1726-1733

Rifapentine and Isoniazid in the Continuation Phase of Treating Pulmonary Tuberculosis
Initial Report

C. M. TAM, S. L. CHAN, C. W. LAM, C. C. LEUNG, K. M. KAM, J. S. MORRIS, and D. A. MITCHISON

Wanchai Polyclinic, Hong Kong; Ruttonjee Hospital, Wanchai, Hong Kong; Shaukeiwan Jockey Club Polyclinic, Hong Kong; Yung Fung Shee Memorial Centre, Kowloon, Hong Kong; London School of Hygiene and Tropical Medicine, London; and St. George's Hospital Medical School, London, United Kingdom

A randomized comparison has been made of three times weekly rifampin plus isoniazid (HR₃) with rifapentine plus isoniazid given once weekly (HRp₁) or on 2 of 3 wk (HRp₁.2/3) in the continuation phase of 6-mo regimens (each starting with an initial 2 mo of 4-drug therapy) for the treatment of pulmonary tuberculosis in 672 Chinese patients in Hong Kong. Because of poor bioavailability of the rifapentine used (produced in China), its dose size was increased from 600 mg initially to about 750 mg in the last third of patients to obtain serum concentrations similar to those with rifapentine of Western origin; all doses were given after a meal promoting absorption. After initial exclusions, an intent to treat analysis, done on the remaining 592 patients, showed 45 adverse treatment events in 7 of 190 HR₃ patients, in 17 of 199 HRp₁ patients, and in 21 of 203 HRp₁.2/3 patients; of these, 42 were bacteriological or radiographic relapses after the end of treatment (HR₃ versus HRp₁, p = 0.04; HR₃ versus HRp₁.2/3, p = 0.01). Patients with organisms initially sensitive or resistant to isoniazid or streptomycin had similar relapse rates. The high relapse rate in the HRp₁ regimen suggests that the rifapentine dose should be increased. Similarity of relapse rates, 8.9% and 10.4%, after the HRp₁ and HRp₁.2/3 regimens, respectively, indicates that irregularity in taking rifapentine/isoniazid could be tolerated. The few adverse side effects in the continuation phase in the rifapentine regimens were less frequent than in the HR₃ regimen.

This article has been cited by other articles:

				N. N. Bock, T. R. Sterling, C. D. Hamilton, C. Pachucki, Y.-C. Wang, D. S. Conwell, A. Mosher, M. Samuels, and A. Vernon A Prospective, Randomized, Double-Blind Study of the Tolerability of Rifapentine 600, 900, and 1,200 mg Plus Isoniazid in the Continuation Phase of Tuberculosis Treatment Am. J. Respir. Crit. Care Med., June 1, 2002; 165(11): 1526 - 1530. [Abstract] [Full Text] [PDF]

				N. Lounis, A. Bentoucha, C. Truffot-Pernot, B. Ji, R. J. O'Brien, A. Vernon, G. Roscigno, and J. Grosset Effectiveness of Once-Weekly Rifapentine and Moxifloxacin Regimens against Mycobacterium tuberculosis in Mice Antimicrob. Agents Chemother., December 1, 2001; 45(12): 3482 - 3486. [Abstract] [Full Text] [PDF]

				E. Miyazaki, R. E. Chaisson, and W. R. Bishai Analysis of Rifapentine for Preventive Therapy in the Cornell Mouse Model of Latent Tuberculosis Antimicrob. Agents Chemother., September 1, 1999; 43(9): 2126 - 2130. [Abstract] [Full Text]

				R. J. O'Brien and A. A. Vernon New Tuberculosis Drug Development . How Can We Do Better? Am. J. Respir. Crit. Care Med., June 1, 1998; 157(6): 1705 - 1707. [Full Text] [PDF]